5-Alpha-Reductase Inhibitors and Combination Therapy.

Füllhase C; Schneider MP

doi:10.1016/j.ucl.2016.04.003

Back

Journal article

5-Alpha-Reductase Inhibitors and Combination Therapy.

Füllhase C Department of Urology, University of Rostock, Ernst-Heydemann-Str. 6, Rostock 18057, Germany. Electronic address: Claudius.fuellhase@uni-rostock.de.
Schneider MP Department of Health Science and Technology, Swiss Federal Institute of Technology Zurich, Brain Research Institute, University of Zurich, Winterthurerstrasse 190, Zürich 8057, Switzerland.

2016-08-01

Published in:

The Urologic clinics of North America. - 2016

English By inhibiting the conversion from testosterone to dihydrotestosterone 5-Alpha reductase inhibitors (5ARIs) are able to hinder prostatic growth, shrink prostate volumes, and improve BPH-related LUTS. 5ARIs are particularly beneficial for patients with larger prostates (>30-40ml). Generally the side effects of 5ARI treatment are mild, and according to the FORTA classification 5ARIs are suitable for frail elderly. 5ARI / alpha-blocker (AB) combination therapy showed the best symptomatic outcome and risk reduction for clinical progression. Combining Phosphodieseterase type 5 inhbibitors (PDE5Is) with 5ARIs counteracts the negative androgenic sexual side effects of 5ARIs, and simultaneously combines their synergistic effects on LUTS.

Language